FRESENIUS SE+CO.KGAA O.N. news, videos and press releases
For more news please use our advanced search feature.
FRESENIUS SE+CO.KGAA O.N. - More news...
FRESENIUS SE+CO.KGAA O.N. - More news...
- EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024
- EQS-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 17.05.2024 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
- EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023
- Prometheus Laboratories Announces Collaboration with Fresenius Kabi on Anser Testing
- EQS-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 17.05.2023 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
- EQS-Adhoc: Fresenius SE & Co. KGaA: Outlook 2023 – Fresenius advances with deconsolidation of Fresenius Medical Care by changing its legal form into a German stock corporation (Aktiengesellschaft)
- EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms review of deconsolidation of Fresenius Medical Care through change of legal form into a stock corporation
- EQS-Adhoc: Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
- EQS-Adhoc: Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised
- DGAP-Adhoc: Fresenius SE & Co. KGaA: Michael Sen to succeed Stephan Sturm as CEO of Fresenius
- DGAP-Adhoc: Fresenius SE & Co. KGaA: Significantly worsening headwinds at Fresenius Medical Care impact Group net income in FY/22; Fresenius SE & Co. KGaA Group guidance revised
- DGAP-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting on May 13, 2022 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
- DGAP-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in on May 21, 2021 according to article 121 AktG with the objective of Europe-wide distribution
- DGAP-Adhoc: Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21
- Fresenius Kabi and ASPEN partner for an expert interview series on omega-3 fatty acid containing parenteral nutrition
- Fresenius Kabi and ASPEN partner for an expert interview series on omega-3 fatty acid containing parenteral nutrition
- Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH
- DGAP-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Bad Homburg on August 28, 2020, according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
- Three Industry Leaders Form New Venture to Create Scalable Manufacturing Platforms for Cell and Gene Therapies
- DGAP-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on May 17, 2019, according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
- DGAP-Adhoc: Fresenius SE & Co. KGaA: Delaware Supreme Court upholds Fresenius' termination of merger agreement with Akorn
- DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019
- DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius confirms and narrows Group guidance for FY 2018
- DGAP-Adhoc: Fresenius SE & Co. KGaA: Delaware court upholds Fresenius' termination of merger agreement with Akorn
- DGAP-Adhoc: Fresenius SE & Co. KGaA: Akorn, Inc. sues Fresenius for consummation of merger agreement after its termination by Fresenius
- DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius terminates merger agreement with Akorn
- DGAP-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on May 18, 2018 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
- DGAP-Adhoc: Fresenius SE & Co. KGaA: Investigation into alleged breaches of FDA data integrity requirements at Akorn, Inc.; Fresenius aims at strong growth in 2018 and confirms mid-term growth targets
- DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius expects meaningful positive effects from US tax reform
- DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius Kabi to strengthen and diversify product portfolio by acquiring Akorn and Merck KGaA's biosimilars business
